Clinical Takeaway
In a controlled crossover trial of healthy males, neither a low (30 mg) nor a high (700 mg) single dose of CBD produced measurable changes in cortical excitability compared to placebo. This suggests CBD may not have meaningful direct anti-seizure activity on its own, and its clinical benefit in conditions like Dravet syndrome and Lennox-Gastaut syndrome likely depends on its pharmacokinetic interaction with clobazam rather than a standalone neurological effect.
#10 Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.
Citation: Gorbenko Andriy A et al.. Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.. Clinical pharmacology and therapeutics. 2026. PMID: 40836528.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This study clarifies that CBD’s clinical efficacy in seizure disorders may depend primarily on its pharmacokinetic interaction with concurrent ASMs like clobazam rather than direct effects on cortical excitability, fundamentally reshaping how clinicians should interpret CBD’s mechanism of action in epilepsy treatment. Understanding this distinction is critical for optimizing polytherapy regimens and predicting CBD’s effectiveness across different patient populations and drug combinations. These findings have significant implications for off-label CBD use in other neurological conditions where direct anticonvulsant activity was presumed but may not actually occur.
Abstract: Cannabidiol (CBD) is approved as an adjunctive treatment of seizures associated with Dravet syndrome, Lennox-Gastaut Syndrome, and tuberous sclerosis. Its therapeutic and adverse effects are thought to arise, at least partly, from a pharmacokinetic interaction with clobazam, another anti-seizure medication (ASM). The goal of this study was to evaluate the intrinsic anti-epileptic and sedative properties of CBD. A randomized, double-blind, placebo-controlled, 3-way crossover trial was conducted in 25 healthy males. On each visit, single doses of 30 mg CBD, 700 mg CBD, or placebo were administered orally. The effects of CBD on cortical excitability were measured using transcranial magnetic stimulation (TMS) combined with electromyography (EMG) and electroencephalography (EEG). Sedative properties were assessed using a validated CNS test battery. Pharmacokinetic sampling was performed. Data were analyzed using a mixed-effects model. CBD did not have significant effects on single pulse and paired pulse TMS-EMG parameters, compared to placebo. Some significant clusters were seen on paired pulse TMS-EEG at 3 hours post-dose for 30 mg CBD, and at 3 and 5 hours post-dose for 700 mg CBD. CBD did not have significant effects on any tests assessing its sedative properties. These results suggest that CBD may lack intrinsic anti-epileptic and sedative properties and that its effects could be primarily a product of interactions with other drugs, notably clobazam.
🧠 This rigorously designed crossover study challenges a common assumption about cannabidiol’s mechanism of action by demonstrating that CBD lacks direct effects on cortical excitability in humans, suggesting its clinical benefit in seizure disorders may depend primarily on pharmacokinetic interactions with co-administered medications like clobazam rather than intrinsic anti-epileptic properties. While this finding is mechanistically important, clinicians should recognize several caveats: the study’s generalizability to patients with active seizure disorders, different genetic profiles affecting drug metabolism, or polypharmacy regimens remains uncertain, and the relevance of cortical excitability measures to complex seizure pathophysiology warrants consideration. The clinical implication is that CBD’s efficacy should not be assumed to extend broadly across seizure types or as monotherapy, and prescribers should continue relying on the robust evidence supporting its use as adjunctive therapy in the three approved indications while remaining cautious about off-label applications pending further mechanistic and clinical data.
| |